Grant: Discovery Grants Program - Individual
University of Toronto
$32,000.00
Porphyrin-based high relaxivity MRI T1 contrast agents for biomedical imaging
EF 2014-15
Résumé
As one of the major clinical imaging modalities, MRI can noninvasively penetrate deep into an intact, opaque object to provide interior 3D information with a high resolution, which has become one of the most powerful diagnostic tools for detecting diseases. It was estimated that almost 50% of clinical MRI scans nowadays used a MRI contrast agent (CA), a new class of pharmacological product which can enhance the contrast and sensitivity of MRI. The intrinsic low relaxivity (a term that defines the efficacy of MRI CA) for most T1 contrast agents has become a critical technical bottle-neck, limiting its broader application and potential in clinical medicine and biomedical research. The current proposal mainly aims to overcome the relaxivity limitation of T1 CA, using a systematic chemical approach based on a well-established Solomon-Bloembergen -Morgan theory, and to develop porphyrin-based high relaxivity T1 CAs with well-suited compatibility for biomedical applications. A series of porphyrin oligomers with systematically programmed chemical and physical parameters, including molecular size, molecular geometry and conformational rigidity, will be designed, synthesized and characterized. The influence of these variables on the T1 relaxivity, together with their pharmacokinetic properties and toxicity, will be investigated, to evaluate their efficacy and safety for biomedical application. In addition, the potential of using the diamagnetic version of these new porphyrin-oligomers for fluorescence imaging and photodynamic therapy (PDT) will also be examined. In this proposal, theoretical prediction, chemical synthesis, spectroscopic characterization, and biological evaluation will be strategically combined. The systematic structural-activity relationship obtained from current study will provide a guidance towards more rational design of MRI CAs in the future. Our long-term goal is to apply this new generation of T1 CAs, in combination with modern MRI technique and advanced molecular targeting strategy, to selectively and noninvasively detect disease, such as cancer, at early stage.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
387704-2010
Name nom
Zhang, Xiaoan
Department département
Physical & Environmental Sciences (Scarborough)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2010
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3603
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Bio-inorganic chemistry
Research subject fr
Chimie bio-inorganique
Partie
5
Nb partie
5
Application title
Porphyrin-based high relaxivity MRI T1 contrast agents for biomedical imaging
Keyword
NSERC
Application summary
As one of the major clinical imaging modalities, MRI can noninvasively penetrate deep into an intact, opaque object to provide interior 3D information with a high resolution, which has become one of the most powerful diagnostic tools for detecting diseases. It was estimated that almost 50% of clinical MRI scans nowadays used a MRI contrast agent (CA), a new class of pharmacological product which can enhance the contrast and sensitivity of MRI. The intrinsic low relaxivity (a term that defines the efficacy of MRI CA) for most T1 contrast agents has become a critical technical bottle-neck, limiting its broader application and potential in clinical medicine and biomedical research. The current proposal mainly aims to overcome the relaxivity limitation of T1 CA, using a systematic chemical approach based on a well-established Solomon-Bloembergen -Morgan theory, and to develop porphyrin-based high relaxivity T1 CAs with well-suited compatibility for biomedical applications. A series of porphyrin oligomers with systematically programmed chemical and physical parameters, including molecular size, molecular geometry and conformational rigidity, will be designed, synthesized and characterized. The influence of these variables on the T1 relaxivity, together with their pharmacokinetic properties and toxicity, will be investigated, to evaluate their efficacy and safety for biomedical application. In addition, the potential of using the diamagnetic version of these new porphyrin-oligomers for fluorescence imaging and photodynamic therapy (PDT) will also be examined. In this proposal, theoretical prediction, chemical synthesis, spectroscopic characterization, and biological evaluation will be strategically combined. The systematic structural-activity relationship obtained from current study will provide a guidance towards more rational design of MRI CAs in the future. Our long-term goal is to apply this new generation of T1 CAs, in combination with modern MRI technique and advanced molecular targeting strategy, to selectively and noninvasively detect disease, such as cancer, at early stage.